Brief: Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine

Syros Pharmaceuticals

06/12/2023 12:06

Dec 6 (Reuters) - Syros Pharmaceuticals Inc  SYRS.O :
    * SYROS ANNOUNCES ENCOURAGING INITIAL DATA FROM RANDOMIZED
SELECT-AML-1 PHASE 2 CLINICAL TRIAL EVALUATING TAMIBAROTENE IN
COMBINATION WITH VENETOCLAX AND AZACITIDINE
    * SYROS PHARMACEUTICALS INC - TRIPLET REGIMEN CONTINUES TO
DEMONSTRATE FAVORABLE TOLERABILITY
    * SYROS PHARMACEUTICALS INC- ADDITIONAL DATA EXPECTED IN
2024
    * SYROS PHARMACEUTICALS INC-  EXPECTS TO COMPLETE PATIENT
ENROLLMENT IN SELECT-MDS-1 IN Q1 OF 2024
    * SYROS PHARMACEUTICALS INC- SEES TO REPORT PIVOTAL CR DATA
BY
MIDDLE OF Q4 OF 2024 FOR SELECT-MDS-1

Source text for Eikon:  ID:nBwbDVH6La 
Further company coverage:  SYRS.O 

 ((Reuters.Briefs@thomsonreuters.com;))